JP2006514038A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006514038A5 JP2006514038A5 JP2004562599A JP2004562599A JP2006514038A5 JP 2006514038 A5 JP2006514038 A5 JP 2006514038A5 JP 2004562599 A JP2004562599 A JP 2004562599A JP 2004562599 A JP2004562599 A JP 2004562599A JP 2006514038 A5 JP2006514038 A5 JP 2006514038A5
- Authority
- JP
- Japan
- Prior art keywords
- reaction
- free
- protection
- process according
- carried out
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1([C@](*2c(ncnc3*)c3N=C2)O[C@@](CO)C1O)O Chemical compound CC1([C@](*2c(ncnc3*)c3N=C2)O[C@@](CO)C1O)O 0.000 description 2
- YBLBEZRLFOVGNV-UZPSGTSLSA-N CC(C12O)[C@@]1(c1c[nH]c3c1N=CNC3=O)O[C@H](CO)C2O Chemical compound CC(C12O)[C@@]1(c1c[nH]c3c1N=CNC3=O)O[C@H](CO)C2O YBLBEZRLFOVGNV-UZPSGTSLSA-N 0.000 description 1
- FBACBJBYARSDEH-PIDKGTLBSA-N CC1([C@H]([n](cc2)c(N=CN3)c2C3=O)O[C@H](CO)C1O)O Chemical compound CC1([C@H]([n](cc2)c(N=CN3)c2C3=O)O[C@H](CO)C1O)O FBACBJBYARSDEH-PIDKGTLBSA-N 0.000 description 1
- ZJTZFMDWQNPYPB-XRAILWEFSA-N CC1([C@H]([n]2c3nc(N)nc(N)c3c(C#N)c2)O[C@H](C[N+]([O-])=O)C1O)O Chemical compound CC1([C@H]([n]2c3nc(N)nc(N)c3c(C#N)c2)O[C@H](C[N+]([O-])=O)C1O)O ZJTZFMDWQNPYPB-XRAILWEFSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43615002P | 2002-12-23 | 2002-12-23 | |
| PCT/US2003/041603 WO2004058792A1 (en) | 2002-12-23 | 2003-12-23 | Process for the production of 3'-nucleoside prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006514038A JP2006514038A (ja) | 2006-04-27 |
| JP2006514038A5 true JP2006514038A5 (cg-RX-API-DMAC7.html) | 2007-01-18 |
Family
ID=32682350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004562599A Pending JP2006514038A (ja) | 2002-12-23 | 2003-12-23 | 3’−ヌクレオシドプロドラッグの生産方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040181051A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1575971A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006514038A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050110611A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100335492C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003300434A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0316868A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2511616A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL169314A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05006865A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20053557L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ540913A (cg-RX-API-DMAC7.html) |
| PL (1) | PL377608A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2005123395A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004058792A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200505040B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| PL359169A1 (en) | 2000-05-26 | 2004-08-23 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| KR20050035194A (ko) | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘 |
| CN101172993A (zh) | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷 |
| AU2003298658A1 (en) | 2002-11-15 | 2004-06-15 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
| US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
| KR20060015542A (ko) * | 2003-04-28 | 2006-02-17 | 이데닉스 (케이만) 리미티드 | 산업 규모의 뉴클레오시드 합성 |
| WO2005123087A2 (en) * | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
| AU2005302448B2 (en) | 2004-10-29 | 2012-07-19 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
| WO2006071619A1 (en) * | 2004-12-23 | 2006-07-06 | Novartis Ag | Compositions for hcv treatment |
| AU2006222563A1 (en) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| CA2602533A1 (en) | 2005-03-29 | 2006-10-05 | Biocryst Pharmaceuticals, Inc. | Use of c-nucleoside analogs for treatment of hepatitis c related viral infections |
| ES2317583T3 (es) * | 2005-09-22 | 2009-04-16 | F. Hoffmann-La Roche Ag | O-acilacion selectiva de nucleosidos. |
| EP1987050A2 (en) * | 2006-02-14 | 2008-11-05 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| CN101460488A (zh) | 2006-04-04 | 2009-06-17 | 弗·哈夫曼-拉罗切有限公司 | 用于hcv治疗的3’,5’-二-o-酰化核苷 |
| WO2010015637A1 (en) * | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| MX2011006890A (es) | 2008-12-23 | 2011-07-20 | Pharmasset Inc | Analogos de nucleosidos. |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| BRPI1004575A2 (pt) | 2009-01-09 | 2016-04-05 | Inhibitex Inc | composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo |
| AP2012006535A0 (en) | 2010-03-31 | 2012-10-31 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorous containing actives |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| SG11202105512PA (en) * | 2018-11-25 | 2021-06-29 | Tnt Medical Corp | Orally active prodrug of gemcitabine |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE29835E (en) * | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FR2562543B1 (fr) * | 1984-04-10 | 1987-09-25 | Elf Aquitaine | Nouveaux phosphonites cycliques, leur preparation et applications |
| NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| CA2083961A1 (en) * | 1990-05-29 | 1991-11-30 | Henk Van Den Bosch | Synthesis of glycerol di- and triphosphate derivatives |
| US5627165A (en) * | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
| US5149794A (en) * | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| US5256641A (en) * | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5157027A (en) * | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
| US5554728A (en) * | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| US5696277A (en) * | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
| SK284054B6 (sk) * | 1996-10-16 | 2004-08-03 | Icn Pharmaceuticals, Inc. | Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie |
| US6248878B1 (en) * | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
| US6472373B1 (en) * | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| EA200700564A1 (ru) * | 1998-02-25 | 2007-08-31 | Эмори Юниверсити | 2`-фторнуклеозиды |
| US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| JP3839667B2 (ja) * | 1998-06-08 | 2006-11-01 | エフ.ホフマン−ラ ロシュ アーゲー | 慢性C型肝炎の処置のためのPeg−INF−アルファ及びリバビリンの使用 |
| JP4979866B2 (ja) * | 1999-09-08 | 2012-07-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 肝臓に特異的なドラッグデリバリーのためのプロドラッグ |
| CA2389745C (en) * | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| CN1740182A (zh) * | 1999-12-22 | 2006-03-01 | 症变治疗公司 | 新的双氨基化膦酸酯前药 |
| US6495677B1 (en) * | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| SK11922002A3 (sk) * | 2000-02-18 | 2003-06-03 | Shire Biochem Inc. | Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom |
| JP2003532643A (ja) * | 2000-04-13 | 2003-11-05 | フアーマセツト・リミテツド | 肝炎ウイルス感染症を治療するための3’−または2’−ヒドロキシメチル置換ヌクレオシド誘導体 |
| US6924270B2 (en) * | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| PL359169A1 (en) * | 2000-05-26 | 2004-08-23 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses |
| US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| EP2141244A1 (en) * | 2000-10-18 | 2010-01-06 | Pharmasset, Inc. | Multiplex quantification of nucleic acids in diseased cells |
| KR20090089922A (ko) * | 2000-10-18 | 2009-08-24 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| AU2002213343A1 (en) * | 2000-10-18 | 2002-04-29 | Schering Corporation | Ribavirin-pegylated interferon alfa HCV combination therapy |
| US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| MXPA03006514A (es) * | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2003024461A1 (en) * | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
| EP1480982A4 (en) * | 2002-02-14 | 2007-08-01 | Pharmasset Inc | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |
| RU2004128943A (ru) * | 2002-02-28 | 2005-04-20 | Байота, Инк. (Us) | Средства, имитирующие нуклеотиды, и их пролекарственные формы |
| US7247621B2 (en) * | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| BR0309581A (pt) * | 2002-05-06 | 2005-03-29 | Genelabs Tech Inc | Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c |
| KR20050035194A (ko) * | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘 |
| KR20050055630A (ko) * | 2002-06-28 | 2005-06-13 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체 |
| TW200418498A (en) * | 2002-09-30 | 2004-10-01 | Genelabs Tech Inc | Nucleoside derivatives for treating hepatitis C virus infection |
| US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| AU2003298658A1 (en) * | 2002-11-15 | 2004-06-15 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
| TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| US7598373B2 (en) * | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
-
2003
- 2003-12-23 MX MXPA05006865A patent/MXPA05006865A/es unknown
- 2003-12-23 CA CA002511616A patent/CA2511616A1/en not_active Abandoned
- 2003-12-23 CN CNB2003801098204A patent/CN100335492C/zh not_active Expired - Fee Related
- 2003-12-23 KR KR1020057011749A patent/KR20050110611A/ko not_active Withdrawn
- 2003-12-23 BR BR0316868-9A patent/BR0316868A/pt not_active IP Right Cessation
- 2003-12-23 NZ NZ540913A patent/NZ540913A/en unknown
- 2003-12-23 EP EP03814400A patent/EP1575971A4/en not_active Withdrawn
- 2003-12-23 RU RU2005123395/04A patent/RU2005123395A/ru not_active Application Discontinuation
- 2003-12-23 AU AU2003300434A patent/AU2003300434A1/en not_active Abandoned
- 2003-12-23 WO PCT/US2003/041603 patent/WO2004058792A1/en not_active Ceased
- 2003-12-23 PL PL377608A patent/PL377608A1/pl not_active Application Discontinuation
- 2003-12-23 JP JP2004562599A patent/JP2006514038A/ja active Pending
- 2003-12-23 US US10/746,395 patent/US20040181051A1/en not_active Abandoned
-
2005
- 2005-06-21 ZA ZA200505040A patent/ZA200505040B/en unknown
- 2005-06-21 IL IL169314A patent/IL169314A0/en unknown
- 2005-07-20 NO NO20053557A patent/NO20053557L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005123395A (ru) | Способ получения 3-нуклеозидных пролекарств | |
| JP4768132B2 (ja) | [2.2.1]ビシクロヌクレオシドの改良された製法 | |
| JP2621123B2 (ja) | 2’‐ジデオキシ‐イソグアノシン類,イソステリック類似体およびイソグアノシン誘導体並びにそれらの使用 | |
| US7999098B2 (en) | Triphosphate oligonucleotide modification reagents and uses thereof | |
| JP2002516256A (ja) | 二環式糖成分を有する新規ヌクレオシド | |
| JPH08225589A (ja) | 修飾オリゴヌクレオチド、それらの製造、およびそれらの使用 | |
| WO2003062257A1 (en) | Deazapurine nucleoside analogs and their use as therapeutic agents | |
| JPH11501287A (ja) | 光に不安定な保護基を有するヌクレオシド誘導体 | |
| WO2004072090A1 (en) | Process for preparing branched ribonucleosides from 1, 2-anhydroribofuranose intermediates | |
| CN100558739C (zh) | 合成被保护的3’-氨基核苷单体 | |
| JP2022534561A (ja) | アミノピリミジン化合物の調製方法 | |
| JP2003514766A (ja) | 活性剤としてルイス酸を用いるオリゴヌクレオチド合成 | |
| CA2254065A1 (en) | Nucleoside derivatives with photoliable protective groups | |
| WO2003051898A1 (en) | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents | |
| Ku et al. | Synthesis of distal and proximal fleximer base analogues and evaluation in the nucleocapsid protein of HIV-1 | |
| JP4887500B2 (ja) | ヌクレオシド類似体またはその塩 | |
| Guo et al. | Discovery of pyrimidine nucleoside dual prodrugs and pyrazine nucleosides as novel anti-HCV agents | |
| KR20200100033A (ko) | 변형된 뉴클레오시드 포스포르아미다이트 | |
| WO2019022158A1 (ja) | 可視光域で光架橋可能な光応答性ヌクレオチドアナログ | |
| Srivastava et al. | Achiral, acyclic nucleic acids: synthesis and biophysical studies of a possible prebiotic polymer | |
| Komatsu et al. | An efficient amination method for manufacturing cytidines | |
| Sari et al. | Nucleosides modified at the base moiety | |
| JP4885963B2 (ja) | ヌクレオシドの選択的o−アシル化 | |
| JP2023503985A5 (cg-RX-API-DMAC7.html) | ||
| JP4174895B2 (ja) | ヌクレオシド誘導体とその製法 |